Research programme: COVID-2019 infection vaccines - CaroGen Corporation
Alternative Names: AVIDIO/CoV-2; AVIDIO/COVID-19; AVIDIO/SARS-CoV-2; CoV-2 vaccines - CaroGen CorporationLatest Information Update: 30 Jul 2021
At a glance
- Originator CaroGen
- Class COVID-19 vaccines; Synthetic vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research COVID 2019 infections
Most Recent Events
- 30 Jul 2021 Early research in COVID-2019 infections (Prevention) in USA (unspecified route)
- 10 Mar 2020 CaroGen Corporation plans clinical trials for COVID-2019 infections (Prevention)
- 08 Oct 2018 CaroGen has patent protection for Artificial Virus (AV) for Infectious Diseases (ID) and Immuno/Oncology (IO) (AVIDIO) platform in USA